ITP Resources

For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

DOPTELET® (avatrombopag) RESOURCE CENTER

For Your Practice

DOVA 1Source brochure

DOVA 1SOURCE OVERVIEW

Detailed information about all of the program offerings

HCP Dosing Guide

HCP DOSING GUIDE

Detailed guidance and information about how to dose and titrate DOPTELET

 

For Your Patients

ITP Doptelet patient brochure

PATIENT BROCHURE

Important information about DOPTELET for patients

 

Additional Resources

PDSA logo

Platelet Disorder Support Association (PDSA)

A non-profit organization founded in 1998 to enhance the lives of patients with ITP and other platelet disorders through education, advocacy, research, and support.

NIH logo

National Heart, Lung, and Blood Institute (NHLBI)

As a division of the National Institutes of Health, the NHLBI provides global leadership for research, training, and education programs to advocate for the treatment and prevention of heart, lung, and blood disorders in order to enhance the health of all individuals.

Dova 1Source logo

Committed to helping patients navigate access to their prescribed therapy

Dova 1Source can help your prescribed patients navigate access at any point through the fulfillment process.

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

In clinical trials, 7% (9/128) of patients with chronic immune thrombocytopenia treated with DOPTELET developed a thromboembolic event. Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency).

DOPTELET should not be administered to patients with chronic immune thrombocytopenia in an attempt to normalize platelet counts. Follow the dosing guidelines to achieve target platelet counts.

Contraindications:  None

Drug Interactions  

Dose adjustments are recommended for patients with chronic immune thrombocytopenia taking moderate or strong dual CYP2C9 and CYP3A4 inducers or inhibitors.

Adverse Reactions

The most common adverse reactions (≥10%) were: headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae and nasopharyngitis.

Please see Full Prescribing Information for DOPTELET® (avatrombopag).

Visit Dova.com for WAC pricing.

 
 

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION FOR DOPTELET

Warnings and Precautions

DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic immune thrombocytopenia. Thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.